Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
NEURON-SPECIFIC ENOLASE AS A MARKER OF BRAIN METASTASIS IN PATIENTS WITH SMALL-CELL LUNG-CARCINOMA
Autore:
VANDEPOL M; TWIJNSTRA A; TENVELDE GPM; MENHEERE PPCA;
Indirizzi:
UNIV LIMBURG HOSP,DEPT NEUROL MAASTRICHT NETHERLANDS UNIV LIMBURG HOSP,DEPT NEUROL MAASTRICHT NETHERLANDS UNIV LIMBURG HOSP,DEPT PULMONOL MAASTRICHT NETHERLANDS UNIV LIMBURG HOSP,DEPT CLIN CHEM MAASTRICHT NETHERLANDS
Titolo Testata:
Journal of neuro-oncology
fascicolo: 2, volume: 19, anno: 1994,
pagine: 149 - 154
SICI:
0167-594X(1994)19:2<149:NEAAMO>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
FOLLOW-UP; CARCINOEMBRYONIC ANTIGEN; BRONCHOGENIC-CARCINOMA; CONSECUTIVE PATIENTS; COMPUTED-TOMOGRAPHY; CEREBRAL METASTASES; TUMOR-MARKER; CANCER; DIAGNOSIS; CHEMOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
30
Recensione:
Indirizzi per estratti:
Citazione:
M. Vandepol et al., "NEURON-SPECIFIC ENOLASE AS A MARKER OF BRAIN METASTASIS IN PATIENTS WITH SMALL-CELL LUNG-CARCINOMA", Journal of neuro-oncology, 19(2), 1994, pp. 149-154

Abstract

Neuron-specific enolase (NSE) is one of the iso-forms of enolase, a glycolytic enzyme found in the neuroendocrine system. NSE is one of themost widely used tumor markers in small-cell lung carcinoma (SCLC). To assess the value of NSE in discriminating between the sites of metastases in SCLC-patients with and without cerebral involvement, serial NSE determinations were performed. Serum NSE was elevated in 76% of thepatients at initial diagnosis. The value did not discriminate betweenthe extent of disease nor between the sites of extrathoracic disease. NSE levels declined significantly at restaging. A persistent, significant rise occurred in patients with relapse of their disease, regardless of the site of relapse. In patients with brain metastases with and without extracranial disease at relapse, the NSE increase was significantly smaller than in patients without intracranial involvement. Thesefindings indicate that serial determination of serum NSE in SCLC-patients may be useful in monitoring tumor activity but not in predicting the site of metastatic disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 13:25:52